The group's principle activity is to provide inhalable cyclosporine, novel antibiotic delivery system, nebulized antibiotic, nasal hydroxycholorquine and cardioprotectant program. The group's services include drug development, pulmonary and cardiac medicine and commercialization. The group operates from United States.
